EPCAM and pancreatic adenocarcinoma: Building upon these findings, we further generated two EpCAM CAR-T cells and verified the tumor-specific immune response, including cell proliferation, upregulation of surface activation markers, cytokine secretion and cytotoxic activity against pancreatic adenocarcinoma cells.